Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials-Reference-Cited by-同舟云学术

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

Published:2019-02-12 Issue:3 Volume:71 Page:367-378
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care Res

Author:

Mease Philip¹,Roussou Euthalia²,Burmester Gerd-Rüdiger³,Goupille Philippe⁴,Gottlieb Alice⁵,Moriarty Susan R.⁶,Benichou Olivier⁶,Adams David H.⁶,Xu Wen⁶,Nash Peter⁷

Affiliation:

1. Swedish Medical Center and University of Washington; Seattle

2. King George Hospital; Goodmayes Essex UK

3. Charité - University Medicine Berlin Free University and Humboldt University Berlin; Germany

4. University of Tours; Tours France

5. New York Medical College; New York

6. Eli Lilly and Company; Indianapolis Indiana

7. University of Queensland Brisbane; Rheumatology Research Unit Sunshine Coast; Brisbane Queensland Australia

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.23738/fullpdf

Reference27 articles.

1. Role of IL-17 in psoriasis and psoriatic arthritis;Raychaudhuri;Clin Rev Allergy Immunol,2013

2. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial;McInnes;Lancet,2015

3. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis;Mease;N Engl J Med,2015

4. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A;Liu;J Inflamm Res,2016

5. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1;Mease;Ann Rheum Dis,2017

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study;Modern Rheumatology Journal;2024-08-20

2. Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET ^® in Japan;Journal of Dermatological Treatment;2024-07-04

3. Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study;Journal of Personalized Medicine;2024-07-03

4. The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis;Immunotherapy;2024-03-21

5. Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA;Modern Rheumatology Journal;2024-02-17